Patient-reported outcomes in randomized clinical trials of systemic therapy for advanced soft tissue sarcomas in adults: A systematic review.
Crit Rev Oncol Hematol
; 197: 104345, 2024 May.
Article
en En
| MEDLINE
| ID: mdl-38582227
ABSTRACT
BACKGROUND:
This systematic review evaluates reporting of patient-reported outcomes (PROs) within randomized clinical trials (RCTs) for advanced soft tissue sarcoma (STS) patients.METHODS:
A systematic literature search from January 2000 - August 2022 was conducted for phase II/III RCTs evaluating systemic treatments in adult patients with advanced STS. Quality of PRO reporting was assessed using the CONSORT PRO extension.RESULTS:
Out of 7294 abstracts, 59 articles were included; comprising 43 RCTs. Only 15 RCTs (35%) included PROs, none as primary endpoints. Only 10 of these RCTs reported PROs, either in the primary (6/10) or secondary publication (1/10) or in both (3/10), with a median time interval of 23 months. The median CONSORT PRO adherence score was 5.5/14, with higher scores in publications focusing exclusively on PROs.CONCLUSION:
These results highlight the need for improved and more consistent PRO reporting to inform patient care in the setting of advanced STS.Palabras clave
Texto completo:
1
Base de datos:
MEDLINE
Asunto principal:
Sarcoma
/
Ensayos Clínicos Controlados Aleatorios como Asunto
/
Medición de Resultados Informados por el Paciente
Límite:
Adult
/
Humans
Idioma:
En
Revista:
Crit Rev Oncol Hematol
Asunto de la revista:
HEMATOLOGIA
/
NEOPLASIAS
Año:
2024
Tipo del documento:
Article